Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Alan Meds vs Eve

Alan Meds
Graded #99

Higher grade

vs+5.099999999999994
Eve
Graded #210

Lower grade

The verdict

Alan Meds takes it — 71.1/100 to 66/100.

Alan Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth platform offering compounded semaglutide and tirzepatide with multiple administration formats including microdosing and oral options.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAlan Meds +18
72
54
Dose & formulationEve +13
75
88
Clinical oversightAlan Meds +3
82
79
Labs & monitoringAlan Meds +1
53
52
FulfillmentAlan Meds +11
78
67
Contract termsAlan Meds +14
55
41
Alan Meds · left barEve · right bar

The numbers

MetricAlan MedsEve
WeighScore71.1/10066/100
GradeCC
Scorecard rank#99#210
Semaglutide$158/mo (compounded)$195/mo (compounded)
Tirzepatide$295/mo (compounded)$195/mo (compounded)
Coverage46 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Alan Meds

Graded #99 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access
  • Multiple administration formats

Where it loses points

  • Limited public information on program details
Eve

Graded #210 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard